Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Staessen

Showing results (61-70 of 693) with videos related to

Pageof 70
Sort By:
Journal of Hypertension|June 5, 2003
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003Jan A Staessen, Ji-Guang Wang, Lutgarde Thijs
Current Opinion in Nephrology and Hypertension|June 19, 2004
Dementia and antihypertensive treatmentWillem H Birkenhäger, Françoise Forette, Jan A Staessen
The New England Journal of Medicine|August 17, 2012
Secondary prevention after ischemic strokeHaifeng Zhang, Franz H Messerli, Jan A Staessen
Journal of Hypertension|July 17, 2004
Design of the Syst-Eur trial and Syst-Eur Phase 2: Thomas Weihrauch's contributionsWillem H Birkenhäger, Jan A Staessen, Alberto Zanchetti
Hypertension (Dallas, Tex. : 1979)|July 7, 2005
Noncardiovascular illness as barrier to antihypertensive treatmentJan A Staessen, Lutgarde Thijs, Willem H Birkenhäger
American Journal of Hypertension|January 21, 2010
More information on the reproducibility of the ambulatory arterial stiffness indexYan Li, Tine W Hansen, Jan A Staessen
The New England Journal of Medicine|September 28, 2018
Ambulatory Blood Pressure and MortalityLutgarde Thijs, Wen-Yi Yang, Jan A Staessen
American Journal of Hypertension|December 20, 2008
Blood pressure variability remains an elusive predictor of cardiovascular outcomeTine W Hansen, Yan Li, Jan A Staessen
Drugs|June 6, 2007
Imidapril: will fewer adverse events translate into better long-term outcomes?Tom Richart, Jan A Staessen, Willem H Birkenhäger
European Heart Journal|April 14, 2009
Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart diseaseJan A Staessen, Tom Richart, Willem H Birkenhäger
Pageof 70

Showing results (61-70 of 693) with videos related to

Sort By:
Pageof 70
Journal of Hypertension|June 5, 2003
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003Jan A Staessen, Ji-Guang Wang, Lutgarde Thijs
Current Opinion in Nephrology and Hypertension|June 19, 2004
Dementia and antihypertensive treatmentWillem H Birkenhäger, Françoise Forette, Jan A Staessen
The New England Journal of Medicine|August 17, 2012
Secondary prevention after ischemic strokeHaifeng Zhang, Franz H Messerli, Jan A Staessen
Journal of Hypertension|July 17, 2004
Design of the Syst-Eur trial and Syst-Eur Phase 2: Thomas Weihrauch's contributionsWillem H Birkenhäger, Jan A Staessen, Alberto Zanchetti
Hypertension (Dallas, Tex. : 1979)|July 7, 2005
Noncardiovascular illness as barrier to antihypertensive treatmentJan A Staessen, Lutgarde Thijs, Willem H Birkenhäger
American Journal of Hypertension|January 21, 2010
More information on the reproducibility of the ambulatory arterial stiffness indexYan Li, Tine W Hansen, Jan A Staessen
The New England Journal of Medicine|September 28, 2018
Ambulatory Blood Pressure and MortalityLutgarde Thijs, Wen-Yi Yang, Jan A Staessen
American Journal of Hypertension|December 20, 2008
Blood pressure variability remains an elusive predictor of cardiovascular outcomeTine W Hansen, Yan Li, Jan A Staessen
Drugs|June 6, 2007
Imidapril: will fewer adverse events translate into better long-term outcomes?Tom Richart, Jan A Staessen, Willem H Birkenhäger
European Heart Journal|April 14, 2009
Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart diseaseJan A Staessen, Tom Richart, Willem H Birkenhäger
Pageof 70